Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Archives
    • Special Issue Archive
    • Ahead of Print
    • Abstracts In Press
    • Subject Collections
    • Editors' Blog
    • Email Alerts
  • Info For
    • Authors
    • Reviewers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • About
    • The JABFM
    • Editorial Board
    • Indexing
  • Classifieds
  • More
    • Email Alerts
    • Feedback
    • ABFM News
    • Folders
    • Help
  • Other Publications
    • abfm

User menu

Search

  • Advanced search
American Board of Family Medicine
  • Other Publications
    • abfm
American Board of Family Medicine

American Board of Family Medicine

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Archives
    • Special Issue Archive
    • Ahead of Print
    • Abstracts In Press
    • Subject Collections
    • Editors' Blog
    • Email Alerts
  • Info For
    • Authors
    • Reviewers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • About
    • The JABFM
    • Editorial Board
    • Indexing
  • Classifieds
  • More
    • Email Alerts
    • Feedback
    • ABFM News
    • Folders
    • Help
  • JABFM On Twitter
  • JABFM On YouTube
  • JABFM On Facebook
Research ArticleSpecial Communication

The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey

Jenny Lam, Jakub Hlávka and Soeren Mattke
The Journal of the American Board of Family Medicine November 2019, 32 (6) 931-940; DOI: https://doi.org/10.3122/jabfm.2019.06.180328
Jenny Lam
the Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA (JM); Price School of Public Policy, University of Southern California, Los Angeles, CA (JH); Center for Economic and Social Research, University of Southern California, Los Angeles, CA (SM).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jakub Hlávka
the Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA (JM); Price School of Public Policy, University of Southern California, Los Angeles, CA (JH); Center for Economic and Social Research, University of Southern California, Los Angeles, CA (SM).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soeren Mattke
the Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA (JM); Price School of Public Policy, University of Southern California, Los Angeles, CA (JH); Center for Economic and Social Research, University of Southern California, Los Angeles, CA (SM).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

References

  1. 1.↵
    1. Selkoe DJ
    . Alzheimer disease and aducanumab: adjusting our approach. Nat Rev Neurol 2019;15:365–366.
    OpenUrl
  2. 2.↵
    EISAI and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018 [Press Release]. Eisai Co., Ltd. and Biogen Inc., July 26 2018.
  3. 3.↵
    1. Liu JL,
    2. Hlávka JP,
    3. Hillestad R,
    4. Mattke S
    . Assessing the preparedness of the U.S. health care system infrastructure for an Alzheimer's treatment. Santa Monica, CA: RAND Corporation; 2017.
  4. 4.↵
    1. Rabinovici GD,
    2. Gatsonis C,
    3. Apgar C,
    4. et al
    . Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA 2019;321:1286–1294.
    OpenUrlCrossRef
  5. 5.↵
    1. Cognat E,
    2. Mouton Liger F,
    3. Troussière AC,
    4. et al
    . What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. BMJ Open 2019;9(5):e026380.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Rajan KB,
    2. Weuve J,
    3. Barnes LL,
    4. Wilson RS,
    5. Evans DA
    . Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study. Alzheimers Dement 2019;15:1–7.
    OpenUrl
  7. 7.↵
    1. Lane CA,
    2. Hardy J,
    3. Schott JM
    . Alzheimer's disease. Eur J Neurol 2018;25:59–70.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Albert MS,
    2. DeKosky ST,
    3. Dickson D,
    4. et al
    . The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270–279.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. McKhann GM,
    2. Knopman DS,
    3. Chertkow H,
    4. et al
    . The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263–269.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Sperling RA,
    2. Aisen PS,
    3. Beckett LA,
    4. et al
    . Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280–292.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Jack CR Jr.,
    2. Knopman DS,
    3. Jagust WJ,
    4. et al
    . Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207–216.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Petersen RC,
    2. Aisen P,
    3. Boeve BF,
    4. et al
    . Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 2013;74:199–208.
    OpenUrlPubMed
  13. 13.↵
    1. Knopman DS,
    2. Petersen RC
    . Mild cognitive impairment and mild dementia: a clinical perspective. Mayo Clin Proc 2014;89:1452–1459.
    OpenUrl
  14. 14.↵
    Safety and Efficacy study of gantenerumab in participants with early Alzheimer's disease (AD). Available from: https://ClinicalTrials.gov/show/NCT03443973. Accessed March 17, 2019.
  15. 15.↵
    Efficacy and Safety study of gantenerumab in participants with early Alzheimer's disease (AD). Available from: https://ClinicalTrials.gov/show/NCT03444870. Accessed March 17, 2019.
  16. 16.↵
    A study to confirm safety and efficacy of BAN2401 in participants with early Alzheimer's disease. Available from: https://ClinicalTrials.gov/show/NCT03887455. Accessed June 22, 2019.
  17. 17.↵
    A study of LY3002813 in participants with early symptomatic Alzheimer's disease (TRAILBLAZER-ALZ). Available from: https://ClinicalTrials.gov/show/NCT03367403. Accessed March 17, 2019.
  18. 18.↵
    A study to evaluate the efficacy and safety of ABBV-8E12 in subjects with early Alzheimer's disease. Available from: https://ClinicalTrials.gov/show/NCT02880956. Accessed March 17, 2019.
  19. 19.↵
    A study to evaluate the efficacy and safety of RO7105705 in patients with prodromal to mild Alzheimer's disease. Available from: https://ClinicalTrials.gov/show/NCT03289143. Accessed March 17, 2019.
  20. 20.↵
    A 24-month study to evaluate the efficacy and safety of E2609 in subjects with early Alzheimer's disease_ (MissionAD2). Available from: https://ClinicalTrials.gov/show/NCT03036280. Accessed March 17, 2019.
  21. 21.↵
    A study of CNP520 versus placebo in participants at risk for the onset of clinical symptoms of Alzheimer's disease. Available from: https://ClinicalTrials.gov/show/NCT03131453. Accessed March 17, 2019.
  22. 22.↵
    A study of CAD106 and CNP520 versus placebo in participants at risk for the onset of clinical symptoms of Alzheimer's disease. Available from: https://ClinicalTrials.gov/show/NCT02565511. Accessed March 17, 2019.
  23. 23.↵
    24 months safety and efficacy study of AADvac1 in patients with mild Alzheimer's disease. Available from: https://ClinicalTrials.gov/show/NCT02579252. Accessed March 17, 2019.
  24. 24.↵
    1. Cummings J,
    2. Lee G,
    3. Ritter A,
    4. Zhong K
    . Alzheimer's disease drug development pipeline: 2018. Alzheimers Dement (N Y) 2018;4:195–214.
    OpenUrlCrossRef
  25. 25.↵
    1. Khan A,
    2. Corbett A,
    3. Ballard C
    . Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets. Expert Rev Neurother 2017;17:683–695.
    OpenUrl
  26. 26.↵
    1. Petersen RC,
    2. Lopez O,
    3. Armstrong MJ,
    4. et al
    . Practice guideline update summary: mild cognitive impairment: report of the Guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 2018;90:126–135.
    OpenUrl
  27. 27.↵
    1. Cordell CB,
    2. Borson S,
    3. Boustani M,
    4. et al
    . Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. Alzheimers Dement 2013;9:141–150.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    Gerontological Society of America (GSA) workgroup on cognitive impairment detection and earlier diagnosis. KAER—A 4-step process to detecting cognitive impairment and earlier diagnosis of dementia. Available from: https://www.geron.org/images/gsa/kaer/gsa-kaer-toolkit.pdf. Published 2017. Accessed March 3, 2019.
  29. 29.↵
    1. Lin JS,
    2. O'Connor E,
    3. Rossom RC,
    4. et al
    . U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. In: Screening for cognitive impairment in older adults: an evidence update for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013.
  30. 30.↵
    1. Tsoi KK,
    2. Chan JY,
    3. Hirai HW,
    4. Wong SY,
    5. Kwok TC
    . Cognitive tests to detect dementia: a systematic review and meta-analysis. JAMA Intern Med 2015;175:1450–1458.
    OpenUrl
  31. 31.↵
    1. Lonie JA,
    2. Tierney KM,
    3. Ebmeier KP
    . Screening for mild cognitive impairment: a systematic review. Int J Geriatr Psychiatry 2009;24:902–915.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Ozer S,
    2. Young J,
    3. Champ C,
    4. Burke M
    . A systematic review of the diagnostic test accuracy of brief cognitive tests to detect amnestic mild cognitive impairment. Int J Geriatr Psychiatry 2016;31:1139–1150.
    OpenUrl
  33. 33.↵
    1. Weissberger GH,
    2. Strong JV,
    3. Stefanidis KB,
    4. Summers MJ,
    5. Bondi MW,
    6. Stricker NH
    . Diagnostic accuracy of memory measures in Alzheimer's dementia and mild cognitive impairment: a systematic review and meta-analysis. Neuropsychol Rev 2017;27:354–388.
    OpenUrl
  34. 34.↵
    1. Williamson JC,
    2. Larner AJ
    . MACE for the diagnosis of dementia and MCI: 3-year pragmatic diagnostic test accuracy study. Dement Geriatr Cogn Disord 2018;45:300–307.
    OpenUrl
  35. 35.↵
    1. Folstein MF,
    2. Folstein SE,
    3. McHugh PR
    . “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    1. Folstein M,
    2. Folstein S
    . Invited reply to “The death knoll for the MMSE: has it outlived its purpose?”. J Geriatr Psychiatry Neurol 2010;23:158–159.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Carnero-Pardo C
    . Should the mini-mental state examination be retired? Neurologia 2014;29:473–481.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Nieuwenhuis-Mark RE
    . The death knoll for the MMSE: has it outlived its purpose? J Geriatr Psychiatry Neurol 2010;23:151–157.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Trzepacz PT,
    2. Hochstetler H,
    3. Wang S,
    4. Walker B,
    5. Saykin AJ
    . Relationship between the Montreal Cognitive Assessment and Mini-Mental State Examination for assessment of mild cognitive impairment in older adults. BMC Geriatr 2015;15:107.
    OpenUrlPubMed
  40. 40.↵
    1. Nasreddine ZS,
    2. Phillips NA,
    3. Bédirian V,
    4. et al
    . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695–699.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Julayanont P,
    2. Brousseau M,
    3. Chertkow H,
    4. Phillips N,
    5. Nasreddine ZS
    . Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer's disease. J Am Geriatr Soc 2014;62:679–684.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Lam B,
    2. Middleton LE,
    3. Masellis M,
    4. et al
    . Criterion and convergent validity of the Montreal Cognitive Assessment with screening and standardized neuropsychological testing. J Am Geriatr Soc 2013;61:2181–2185.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Mellor D,
    2. Lewis M,
    3. McCabe M,
    4. et al
    . Determining appropriate screening tools and cut-points for cognitive impairment in an elderly Chinese sample. Psychol Assess 2016;28:1345–1353.
    OpenUrl
  44. 44.↵
    1. Luis CA,
    2. Keegan AP,
    3. Mullan M
    . Cross validation of the Montreal Cognitive Assessment in community dwelling older adults residing in the Southeastern US. Int J Geriatr Psychiatry 2009;24:197–201.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    1. Roalf DR,
    2. Moberg PJ,
    3. Xie SX,
    4. Wolk DA,
    5. Moelter ST,
    6. Arnold SE
    . Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging. Alzheimers Dement 2013;9:529–537.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    1. Ciesielska N,
    2. Sokołowski R,
    3. Mazur E,
    4. Podhorecka M,
    5. Polak-Szabela A,
    6. Kedziora-Kornatowska K
    . Is the Montreal Cognitive Assessment (MoCA) test better suited than the Mini-Mental State Examination (MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? Meta-analysis. Psychiatr Pol 2016;50:1039–1052.
    OpenUrl
  47. 47.↵
    1. Freitas S,
    2. Simões MR,
    3. Alves L,
    4. Santana I
    . Montreal cognitive assessment: validation study for mild cognitive impairment and Alzheimer disease. Alzheimer Dis Assoc Disord 2013;27:37–43.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Fujiwara Y,
    2. Suzuki H,
    3. Yasunaga M,
    4. et al
    . Brief screening tool for mild cognitive impairment in older Japanese: validation of the Japanese version of the Montreal Cognitive Assessment. Geriatr Gerontol Int 2010;10:225–232.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Tiffin-Richards FE,
    2. Costa AS,
    3. Holschbach B,
    4. et al
    . The Montreal Cognitive Assessment (MoCA)—A sensitive screening instrument for detecting cognitive impairment in chronic hemodialysis patients. PLoS One 2014;9(10):e106700.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Hsieh S,
    2. McGrory S,
    3. Leslie F,
    4. et al
    . The Mini-Addenbrooke's Cognitive Examination: a new assessment tool for dementia. Dement Geriatr Cogn Disord 2015;39:1–11.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Larner AJ
    . MACE versus MoCA: equivalence or superiority? Pragmatic diagnostic test accuracy study. Int Psychogeriatr 2017;29:931–937.
    OpenUrl
  52. 52.↵
    1. Berg JL,
    2. Durant J,
    3. Léger GC,
    4. Cummings JL,
    5. Nasreddine Z,
    6. Miller JB
    . Comparing the electronic and standard versions of the Montreal Cognitive Assessment in an outpatient memory disorders clinic: a validation study. J Alzheimers Dis 2018;62:93–97.
    OpenUrl
  53. 53.↵
    1. Wild K,
    2. Howieson D,
    3. Webbe F,
    4. Seelye A,
    5. Kaye J
    . Status of computerized cognitive testing in aging: a systematic review. Alzheimers Dement 2008;4:428–437.
    OpenUrlCrossRefPubMedWeb of Science
  54. 54.↵
    1. Darby DG,
    2. Fredrickson J,
    3. Pietrzak RH,
    4. Maruff P,
    5. Woodward M,
    6. Brodtmann A
    . Reliability and usability of an internet-based computerized cognitive testing battery in community-dwelling older people. Computers Human Behav 2014;30:199–205.
    OpenUrl
  55. 55.↵
    1. Buckley RF,
    2. Sparks KP,
    3. Papp KV,
    4. et al
    . Computerized cognitive testing for use in clinical trials: a comparison of the NIH Toolbox and Cogstate C3 batteries. J Prev Alzheimers Dis 2017;4:3–11.
    OpenUrl
  56. 56.↵
    1. Denboer JW,
    2. Nicholls C,
    3. Corte C,
    4. Chestnut K
    . National Institutes of Health Toolbox Cognition Battery. Arch Clin Neuropsychol 2014;29:692–694.
    OpenUrlCrossRef
  57. 57.↵
    1. Yang H,
    2. Lyutvinskiy Y,
    3. Herukka SK,
    4. Soininen H,
    5. Rutishauser D,
    6. Zubarev RA
    . Prognostic polypeptide blood plasma biomarkers of Alzheimer's disease progression. J Alzheimers Dis 2014;40:659–666.
    OpenUrl
  58. 58.↵
    1. Hye A,
    2. Riddoch-Contreras J,
    3. Baird AL,
    4. et al
    . Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement 2014;10:799–807.e792.
    OpenUrlCrossRefPubMedWeb of Science
  59. 59.↵
    1. DeMarshall CA,
    2. Nagele EP,
    3. Sarkar A,
    4. et al
    . Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers. Alzheimers Dement (Amst) 2016;3:51–62.
    OpenUrl
  60. 60.↵
    1. Yamamoto-Imoto H,
    2. Zamolodchikov D,
    3. Chen ZL,
    4. et al
    . A novel detection method of cleaved plasma high-molecular-weight kininogen reveals its correlation with Alzheimer's pathology and cognitive impairment. Alzheimers Dement (Amst) 2018;10:480–489.
    OpenUrl
  61. 61.↵
    1. Varma VR,
    2. Varma S,
    3. An Y,
    4. et al
    . Alpha-2 macroglobulin in Alzheimer's disease: a marker of neuronal injury through the RCAN1 pathway. Mol Psychiatry 2017;22:13–23.
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. Zarrouk A,
    2. Debbabi M,
    3. Bezine M,
    4. et al
    . Lipid biomarkers in Alzheimer's disease. Curr Alzheimer Res 2018;15:303–312.
    OpenUrl
  63. 63.↵
    1. Chintamaneni M,
    2. Bhaskar M
    . Biomarkers in Alzheimer's disease: a review. ISRN Pharmacol 2012;2012:984786.
    OpenUrlPubMed
  64. 64.↵
    1. Donohue MC,
    2. Moghadam SH,
    3. Roe AD,
    4. et al
    . Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. Alzheimers Dement 2015;11:1069–1079.
    OpenUrl
  65. 65.↵
    1. Olsson B,
    2. Lautner R,
    3. Andreasson U,
    4. et al
    . CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol 2016;15:673–684.
    OpenUrlCrossRefPubMed
  66. 66.↵
    1. Ritchie C,
    2. Smailagic N,
    3. Noel-Storr AH,
    4. et al
    . Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2014(6):Cd008782.
  67. 67.↵
    1. Nakamura A,
    2. Kaneko N,
    3. Villemagne VL,
    4. et al
    . High performance plasma amyloid-β biomarkers for Alzheimer's disease. Nature 2018;554:249–254.
    OpenUrlCrossRef
  68. 68.↵
    1. Fandos N,
    2. Perez-Grijalba V,
    3. Pesini P,
    4. et al
    . Plasma amyloid beta 42/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst) 2017;8:179–187.
    OpenUrl
  69. 69.↵
    1. Tzen KY,
    2. Yang SY,
    3. Chen TF,
    4. et al
    . Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease. ACS Chem Neurosci 2014;5:830–836.
    OpenUrlCrossRefPubMed
  70. 70.↵
    1. Blennow K
    . A review of fluid biomarkers for Alzheimer's disease: moving from CSF to blood. Neurol Ther 2017;6(Suppl 1):15–24.
    OpenUrl
  71. 71.↵
    1. Mielke MM,
    2. Hagen CE,
    3. Xu J,
    4. et al
    . Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement 2018;14:989–997.
    OpenUrl
  72. 72.↵
    1. Chen Z,
    2. Mengel D,
    3. Keshavan A,
    4. et al
    . Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease. Alzheimers Dement 2019;15:487–496.
    OpenUrl
  73. 73.↵
    1. Mattsson N,
    2. Andreasson U,
    3. Zetterberg H,
    4. Blennow K
    . Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol 2017;74:557–566.
    OpenUrl
  74. 74.↵
    1. Abbasi J
    . A retinal Scan for Alzheimer disease. JAMA 2017;318:1314.
    OpenUrl
  75. 75.↵
    1. Koronyo-Hamaoui M,
    2. Koronyo Y,
    3. Ljubimov AV,
    4. et al
    . Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. NeuroImage 2011;54(Suppl 1):S204–S217.
    OpenUrlCrossRefPubMedWeb of Science
  76. 76.↵
    1. Garrard P,
    2. Nemes V,
    3. Nikolic D,
    4. Barney A
    . Motif discovery in speech: application to monitoring Alzheimer's disease. Curr Alzheimer Res 2017;14:951–959.
    OpenUrl
  77. 77.↵
    1. Khodabakhsh A,
    2. Demiroglu C
    . Analysis of speech-based measures for detecting and monitoring Alzheimer's disease. Methods Mol Biol 2015;1246:159–173.
    OpenUrl
  78. 78.↵
    1. Beltrán J,
    2. Garcia-Vazquez MS,
    3. Benois-Pineau J,
    4. Gutierrez-Robledo LM,
    5. Dartigues JF
    . Computational techniques for eye movements analysis towards supporting early diagnosis of Alzheimer's disease: A Review. Comput Math Methods Med 2018;2018:2676409.
    OpenUrl
  79. 79.↵
    1. Silva MME,
    2. Mercer PBS,
    3. Witt MCZ,
    4. Pessoa RR
    . Olfactory dysfunction in Alzheimer's disease systematic review and meta-analysis. Dement Neuropsychol 2018;12:123–132.
    OpenUrl
  80. 80.↵
    1. Jung HJ,
    2. Shin IS,
    3. Lee JE
    . Olfactory function in mild cognitive impairment and Alzheimer's disease: A meta-analysis. Laryngoscope 2019;129:362–369.
    OpenUrl
  81. 81.↵
    1. Velayudhan L
    . Smell identification function and Alzheimer's disease: a selective review. Curr Opin Psychiatry 2015;28:173–179.
    OpenUrlPubMed
  82. 82.↵
    1. Horvath A,
    2. Szucs A,
    3. Csukly G,
    4. Sakovics A,
    5. Stefanics G,
    6. Kamondi A
    . EEG and ERP biomarkers of Alzheimer's disease: a critical review. Front Biosci (Landmark Ed) 2018;23:183–220.
    OpenUrl
  83. 83.↵
    1. Nobukawa S,
    2. Yamanishi T,
    3. Nishimura H,
    4. Wada Y,
    5. Kikuchi M,
    6. Takahashi T
    . Atypical temporal-scale-specific fractal changes in Alzheimer's disease EEG and their relevance to cognitive decline. Cogn Neurodyn 2019;13:1–11.
    OpenUrl
  84. 84.↵
    1. Kanda PAM,
    2. Oliveira EF,
    3. Fraga FJ
    . EEG epochs with less alpha rhythm improve discrimination of mild Alzheimer's. Computer methods and programs in biomedicine 2017;138:13–22.
    OpenUrl
  85. 85.↵
    U.S. Census Bureau, Population Division. Projected 5-Year Age Groups and Sex Composition: Main Projections Series for the United States, 2017–2060. Available from: https://www.census.gov/data/tables/2017/demo/popproj/2017-summary-tables.html. Accessed January 31, 2019.
  86. 86.
    1. Gauthier S,
    2. Reisberg B,
    3. Zaudig M,
    4. et al
    . Mild cognitive impairment. Lancet 2006;367:1262–1270.
    OpenUrlCrossRefPubMedWeb of Science
  87. 87.↵
    Will Europe be ready for the treatment of Alzheimer's disease? Lancet Neurol 2018;17:1025.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of the American Board of Family     Medicine: 32 (6)
The Journal of the American Board of Family Medicine
Vol. 32, Issue 6
November-December 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Board of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey
(Your Name) has sent you a message from American Board of Family Medicine
(Your Name) thought you would like to see the American Board of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey
Jenny Lam, Jakub Hlávka, Soeren Mattke
The Journal of the American Board of Family Medicine Nov 2019, 32 (6) 931-940; DOI: 10.3122/jabfm.2019.06.180328

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey
Jenny Lam, Jakub Hlávka, Soeren Mattke
The Journal of the American Board of Family Medicine Nov 2019, 32 (6) 931-940; DOI: 10.3122/jabfm.2019.06.180328
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Discussion
    • Notes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • New Research on Back Pain, Diet and Diabetes, Advanced Care Planning, and Other Issues Frequently Seen in Family Medicine
  • Google Scholar

More in this TOC Section

  • Clinical Quality Measures: A Challenge for–and to–Family Physicians
  • Motivational Interviewing Strategies for Addressing COVID-19 Vaccine Hesitancy
  • Stalled Progress: Medical School Dean Demographics
Show more Special Communication

Similar Articles

Keywords

  • Alzheimer Disease
  • Amyloid Beta-Peptides
  • Biomarkers
  • Cognitive Dysfunction
  • Dementia
  • Diagnostic Tests
  • Disease Progression
  • Mental Status and Dementia Tests
  • Primary Health Care
  • Sensitivity and Specificity

Navigate

  • Home
  • Current Issue
  • Past Issues

Authors & Reviewers

  • Info For Authors
  • Info For Reviewers
  • Submit A Manuscript/Review

Other Services

  • Get Email Alerts
  • Classifieds
  • Reprints and Permissions

Other Resources

  • Forms
  • Contact Us

© 2022 American Board of Family Medicine

Powered by HighWire